Added to YB: 2025-12-02
Pitch date: 2025-11-28
NOVO-B.CO [neutral]
Novo Nordisk A/S
-22.25%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 304.68
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | Stocks Update 28/11/2025 - NOVOB – Go Evoke, go broke
NOVO-B.CO (update): Evoke Alzheimer's drug failed Phase III trials, missing statistically significant reduction in disease progression. Heavy selloff despite weak prior sentiment. Trades at discounted 13.6x 2026 consensus earnings, 3.7% yield reflects lowered expectations.
Read full article (1 min)